Top executives at Boston Scientific Corp. said on Monday they are confident their deal to buy Guidant Corp. for about $25 billion will go through despite Guidant’s recall of some products and an existing takeover offer from Johnson & Johnson.
*For more on this story,
read the full Reuters article.
